Real-world data on the infliximab biosimilar CT-P13 (Remsima®) in inflammatory bowel disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Real-world data on the infliximab biosimilar CT-P13 (Remsima®) in inflammatory bowel disease

Published:2021-12-26 Issue:36 Volume:9 Page:11285-11299
ISSN:2307-8960
Container-title:World Journal of Clinical Cases
language:
Short-container-title:WJCC

Author:

Huguet Jose María,Cortés Xavier,Bosca-Watts Marta Maia,Aguas Marian,Maroto Nuria,Martí Lidia,Amorós Cirilo,Paredes Jose María

Publisher

Baishideng Publishing Group Inc.

Subject

General Medicine

Reference50 articles.

1. Crohn’s disease

2. Ulcerative colitis

3. Quality of life in inflammatory bowel diseases: it is not all about the bowel

4. Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil

5. Clinical implications of mucosal healing for the management of IBD

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical experience of using biosimilars in Crohn’s disease and their effectiveness;Expert Opinion on Biological Therapy;2024-09-13

2. Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease;Expert Opinion on Biological Therapy;2024-07-02

3. Impact on direct and indirect costs of switching patients with inflammatory bowel disease from intravenous to subcutaneous infliximab (CT-P13);BMJ Open Gastroenterology;2023-02

4. Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study;Biomedicines;2022-08-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3